Mein Warenkorb

CytoPak ActiveMax® Human DLL4 μBeads, premium grade (for cells, 5.5μm)

User Reviews
Product Number/Spec
Price
Menge
MBS-C038-25mg
$15280.00
ETA of in-stock products:2 business days
Gesamtanzahl Product Amount$ 0

Product Details

  • Product
    Size
    Amount
    CytoPak ActiveMax® Human DLL4 μBeads, premium grade (for cells, 5.5 μm)
    25 mg
    2.5×10⁸ beads
  • DLL4 PRODUCT SHOW

    CytoPak ActiveMax® Human DLL4 μBeads, Premium Grade (for cells, 5.5 μm) are 5.5 μm superparamagnetic beads covalently conjugated with recombinant Human DLL4 Protein that are supplied in a sterile, liquid-ready format within medical-grade multilayer film packaging, featuring dual weldable interfaces: a proximal TPE tubing (1/8" ID × 1/4" OD) and distal PVC tubing (3/32" ID × 5/32" OD) for direct aseptic connectivity to cell culture bags. This ready-to-use design eliminates reconstitution steps, enhances biosafety, and makes ex vivo manufacturing processes more convenient. CytoPak ActiveMax® Human DLL4 μBeads make it ideal for scalable iPSC production requiring closed-system assurance and controlledsterility.

  • Product Description

    CytoPak ActiveMax® Human DLL4 μBeads, premium grade (for cells) are produced under sterile manufacturing conditions (ISO 5), and no animal- or human-derived components are used throughout the production process. It is produced under our rigorous quality control system that includes a comprehensive set of tests including sterility and endotoxin tests.

  • Application

    CytoPak ActiveMax® Human DLL4 μBeads, premium grade (for cells) are optimized for large-scale in vitro differentiation of induced pluripotent stem cells (iPSCs) in systems such as cellbags, or stirred-tank bioreactors. The beads functionally mimic thymic DLL4+ epithelial cells by engaging Notch receptors (e.g., Notch1/2) on hematopoietic stem/progenitor cells (HSPCs), thereby activating downstream Notch signaling pathways to drive lineage-specific differentiation. A representative application case is exemplified by ActiveMax® Human DLL4 μBeads, premium grade (for cells), which induce the differentiation of CD34+ hematopoietic stem cells into progenitor T cells lineage (proT cells), Natural Killer (NK) cells lineages etc. under in vitro conditions with the specialized culture media and cytokines supplementation. This product provides a powerful tool for developing stem cell-based immunotherapies.
    The dosage and performance of CytoPak ActiveMax® Human DLL4 μBeads, premium grade (for cells) vary with the differentiation of cell donor, culture media, cytokines supplementation, and target cell lineages etc. It is recommended to optimize the experiment parameters using small-size product (Cat. No. MBS-C013) prior to scaling up.

  • Storage

    This product is supplied and shipped as sterile liquid solution with dry ice, please inquire the shipping cost. Upon receipt, store it immediately at -70°C or lower for long term storage. This product is stable after storage at: • -20˚C for 3 months. • -70°C for 24 months.

    Please protect from light and avoid repeated freeze-thaw cycles.

  • Sterility

    Negative

  • Endotoxin

    Less than 0.002 EU per μg by the LAL method / rFC method.

  • Mycoplasma

    Negative

  • Important Note

    This product is for research use only and not intended for therapeutic or in vivo diagnostic use.

  • ACRO Quality Management System

    1. QMS(ISO, GMP)
    2. Quality Advantages
    3. Quality Control Process

Kunden haben auch angesehen

Data Display

  • FACS Data

     DLL4 FACS

    Assay of human DLL4 protein on the μBeads surface by Flow cytometry. CytoPak ActiveMax® Human DLL4 μBeads, Premium Grade (for cells, 5.5 μm) (Cat. No. MBS-C038) were stained with PE labeled anti-human DLL4 antibody and analyzed by flow cytometry.

    Protocol

User Reviews
Publish Comment

Frontier Progress

 
Drug Development Progress
  • English Name:

    Delta-like protein 4

  • Category:

  • Listed Drugs Count:

    0 Details

  • Clinical Drugs Count:

    3 Details

  • Highest R&D Stage:

    Phase 3 Clinical

Drug Candidate Licensing
More
  • Basic Product Information
  • Product Details
  • Kunden haben auch angesehen
  • Data Display
  • User Reviews
Kontaktieren Sie uns